BioPharm International, JanuaryFebruary 2025

Personalized medicine is a trend that continues to impact innovation and business decisions in the biopharma industry.

Survey results show that being intellectually stimulated and getting assigned challenging projects are two key drivers of employee satisfaction, yet job training is lacking.

Development of new modalities of biotherapeutic molecules will rely on manufacturing, regulatory, and collaborative support.

Cell-line engineering and media formulation improvements are leading to greater performance.

Rapid market growth in biologics is helping the packaging market expand as well, but the complex nature of biologics and the desire for personalized therapies present unique hurdles to make packaging solutions cost-effective and safe for patients.

Developers save money and time while accessing expertise.

The optimization of processes for the development and manufacture of biopharmaceuticals is pivotal for producing quality products.

AI regulations in healthcare are rapidly evolving, and one should consult with regulatory subject matter experts, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.

If the conditions prove optimal, 2025 could be a prosperous year for bio/pharma business deals.